Nov112026

MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced anal cancer

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved retifanlimab (ZYNYZ) for the treatment of adults with squamous cell carcinoma of the anal canal (SCAC).

Leave a Reply

Your email address will not be published.